Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284420 · ClinicalTrials.gov registry record · Phase 2
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
A Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, sponsored by argenx.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 5
- Study locations
NCT07284420 is a Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis that is actively recruiting participants, run by argenx. The registered enrollment target is 70 participants, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (63% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT07284420, a Phase 2 study of Myasthenia Gravis and Generalized Myasthenia Gravis, is actively recruiting participants, sponsored by argenx.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects and improve their quality of life. The aim of this ISA1 is to evaluate the safety and therapeutic relevance of empasiprubart as add-on therapy to efgartigimod in participants with AChR-Ab seropositive generalized myasthenia gravis. The ADAPT Forward master protocol is registered on https://clinicaltrials.gov/study/NCT07294170
Conditions Studied
Interventions
- BIOLOGICAL Efgartigimod IV
- BIOLOGICAL Empasiprubart IV
Study Locations (5)
California
- Profound Research LLC - Carlsbad - Carlsbad
Florida
- Visionary Investigators Network - Miami
New York
- Dent Neurologic Institute - Amherst - Amherst
Tennessee
- Erlanger Health System - Chattanooga
Texas
- National Neuromuscular Research Institute - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-12-19 |
| Est. Completion | 2028-03-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07284420
The ClinicalTrials.gov registry entry for NCT07284420 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 189-participant average among 32 other Myasthenia Gravis trials with a reported enrollment target (63% lower). The listed sponsor is argenx, which has 49 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Myasthenia Gravis appearing as the primary indexed condition, and to 2 interventions - of which Efgartigimod IV is the first listed.
NCT07284420 reports 5 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, New York.
Frequently Asked Questions
What is clinical trial NCT07284420 about?
NCT07284420 is a clinical study titled "ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod". This study is part of the ADAPT Forward platform study (NCT07294170). ADAPT Forward is a platform study with the aim to look at how safe different drugs are and how well they work for people with myasthenia gravis. The goal is to find the best therapeutic approach to reduce patients' side effects an...
What is the current status of trial NCT07284420?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2025-12-19. Estimated completion is 2028-03-07.
What conditions does trial NCT07284420 study?
This clinical trial studies the following conditions: Myasthenia Gravis, Generalized Myasthenia Gravis, gMG, Generalized Myasthenia Gravis (gMG), MG.
What interventions are being tested in trial NCT07284420?
The interventions under investigation include: Efgartigimod IV (BIOLOGICAL), Empasiprubart IV (BIOLOGICAL).
Who is sponsoring clinical trial NCT07284420?
This trial is sponsored by argenx, which has 49 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284420 being conducted?
This trial has 5 study locations across California, Florida, New York, Tennessee, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myasthenia Gravis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RECRUITING · Phase 2
-
A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RECRUITING · Phase 2
-
BeatMG: Phase II Trial of Rituximab In Myasthenia Gravis
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
COMPLETED · Phase 2
-
A Study of RVT-1401 in Myasthenia Gravis (MG) Patients
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.